Loading
A phase 2 trial of Oxaliplatin, Capecitabine and Nivolumab in gastric & gastro-oesophageal junction cancer, run by Ono Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) is a phase 2 interventional study registered as NCT06256328 by Ono Pharmaceutical Co., Ltd., with 226 participants enrolled, started 2024-01-10 and due to reach its primary completion in 2025-10-09. Interventions recorded: ONO-4578, Oxaliplatin, Capecitabine, S-1, Nivolumab and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Deciphera Pharmaceuticals (Ono), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono), Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Deciphera Pharmaceuticals (Ono), Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/